<DOC>
	<DOCNO>NCT02337270</DOCNO>
	<brief_summary>This phase 1 study , healthy volunteer previously immunize bacillus Calmette Guerin ( BCG ) , evaluate safety immune response develop blood lung follow administration aerosol new experimental adenovirus-based vaccine tuberculosis ( TB ) , Ad5Ag85A .</brief_summary>
	<brief_title>Phase 1 Clinical Trial Evaluate Safety Immunogenicity Adenovirus-based Tuberculosis Vaccine Administered Aerosol</brief_title>
	<detailed_description>This phase 1 , open label study evaluate safety immunogenicity single administration escalate dos recombinant replication deficient human adenoviral ( Ad5 ) TB vaccine contain immunodominant antigen Ag85A deliver respiratory tract aerosol healthy volunteer history BCG immunization . 36 healthy volunteer enrol administered escalating dos vaccine use AeroNeb Solo Vibrating Mesh Nebulizer . At high dose , participant randomize inhaled intramuscular administration . Cellular immune response lung peripheral blood evaluate</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Adenoviridae Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Healthy human subject 18 55 year age history BCG vaccination . 2 . HIV antibody negative 3 . Able understand comply protocol requirement instruction ; able attend schedule study visit complete require investigation . 4 . For woman , negative pregnancy test practice two acceptable form contraception duration study ( barrier contraceptive , birth control pill , surgically sterile , postmenopausal 2 year , abstinence ) 5 . For men , use barrier contraception duration study 1 . Pregnant lactate woman 2 . Subjects acute chronic illness include active tuberculosis , relevant finding physical examination receive drug treatment opinion investigator likely affect immune system include current use inhale nasal steroid . 3 . Subjects history bleed disorder receive drug treatment opinion investigator may increase risk bleed 4 . Subjects history respiratory disease , e.g . asthma , chronic bronchitis , chronic obstructive pulmonary disease ( COPD ) . 5 . Current smoker exsmokers quit within last year , report subject 6 . Subjects clinically significant abnormality baseline spirometry test 7 . Any healthrelated condition study bronchoscopy contraindicate 8 . Subjects history active latent TB infection whose PBMC 's responsive ESAT6/CFP10 stimulation use commercial interferon gamma release assay TB [ consistent latent TB infection ] . 9 . Subjects whose baseline laboratory value outside normal range unless abnormality consider clinical relevance Investigator . A single repeat test allow screening period . 10 . Subjects whose use alcohol drug would , opinion investigator , interfere adherence study protocol . 11 . Subjects use , history use , inhaled cocaine , metamphetamine inhale smoke recreational drug . Subjects give history last smoking marijuana year ago may enrol . 12 . Failure provide write consent . 13 . Known allergy vaccine component 14 . Previous vaccination Ad5Ag85A experimental TB vaccine 15 . Known exposure active TB within past 6 month subject whose occupation put increase risk TB exposure ( base Hamilton Health Science/St Joseph Healthcare list high risk personnel ) 16 . Any abnormality chest xray suggestive active remote tuberculosis infection evidence chestxray clinically significant respiratory disease . 17 . PPD skin test within last 12 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Tuberculosis</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Aerosol</keyword>
	<keyword>Adenovirus</keyword>
	<keyword>Immunogenicity</keyword>
</DOC>